Adverum Biotechnologies, Inc.
Long
Aggiornato

ADVM reiteration

186
With the recent advancements about the possible change of board members and the earnings report, finally ADVM should start its climb. The first target is $3.80.
Nota
Decrease in the short volume ratio on the stock is also a positive sign. Despite a penny increment sell wall, we are expecting the climb to resume.
Nota
It is making its comeback. With the institutional support for the success of the company, my target price is $5.60 in the short to middle term. As soon as the issues with the Phase 2 incidence is discovered, the price will slowly regain its valued range of $15-$20.

Declinazione di responsabilità

Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.